ORIGINAL ARTICLE

Changes of fibrinolytic system in thrombolytic resuscitation of pulmonary thromboembolism-induced cardiac arrest model

Nan Tong  |  Chunsheng Li

Department of Emergency, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China

Correspondence
Chunsheng Li, Department of Emergency, Beijing Chao-Yang Hospital, Capital Medical University, No.8 Gongti South Road, Chaoyang District, Beijing 100020, China.
Email: lcscyy@163.com

Abstract
The objective of this study is to explore the changes in the coagulation and fibrinolysis system in an animal model with pulmonary embolism after cardiopulmonary bypass and to provide a theoretical basis for clinical practice. An animal model of cardiac arrest due to pulmonary embolism was established for venous thrombus (10-15 mL) in the left external jugular vein of 21 pigs. Computed tomography (CT) pulmonary arteriography was performed after the recovery of the underlying state, cardiac arrest state and spontaneous circulation, and then thrombolysis and cardiopulmonary resuscitation (recombinant tissue plasminogen activator [t-PA] 50 mg) were performed immediately. The changes of tissue factor (TF), tissue factor pathway inhibitor (TFPI), t-PA and plasminogen activator inhibitor-1 (PAI-1) in the blood were detected by ELISA. The blood samples were collected immediately, 1, 2, 4 and 6 hours after the recovery of spontaneous circulation. Data from animals that were successfully resuscitated at different time points were compared using a repeated measures one-way analysis of variance. Seventeen pigs had cardiac arrest after 10 to 15 mL of thrombus injection, and the other four had cardiac arrest after 5 to 8 mL of additional thrombus. Nine pigs survived 6 hours of cardiopulmonary resuscitation. CT pulmonary angiogram showed pulmonary artery obstruction. TF levels were increased compared with basal status, but there was no statistical difference (P > .05). TFPI levels were higher at 1, 2, 4 and 6 hours after recovery of spontaneous circulation compared with basal state (P < .05); t-PA levels were higher at cardiac arrest, and immediately after recovery of spontaneous circulation compared with basal state. There was a statistical difference in PAI-1 level at 1, 2, 4 and 6 hours after recovery of spontaneous circulation (P < .05). There was no statistical difference in PAI-1 level at each stage compared with basal state (P > .05). TFPI has a certain influence on the coagulation and thrombosis regulation of the body, and the increase in fibrinolytic
activity has a positive promoting effect on the thrombolysis. It provided the theoretical basis of clinical treatment of thrombotic diseases.

**KEYWORDS**
- fibrinolytic system
- pulmonary embolism
- cardiac arrest
- thrombolytic resuscitation

## INTRODUCTION

In recent years, sudden death due to cardiac arrest has seriously threatened human life safety, and the causes of cardiac arrest are diverse. In addition to cardiac causes, there is evidence that pulmonary embolism (PE) can also lead to cardiac arrest.\(^1\) Despite notable progress in the diagnosis and treatment of PE, it remains a serious burden of socioeconomic disease. PE is due to thrombus from the venous system or right heart obstructing the pulmonary artery system or its branches.\(^2\) However, due to hemodynamic disorders, some patients with acute pulmonary thromboembolism still have a high mortality rate. PE is a common cardiovascular disease (CVD) and one of the three most frequent fatal CVDs.\(^3\) The number of patients with PE is about 2 million per year and the number of deaths is 90 million worldwide.\(^4\) Mortality rates amount to 45% and PE rates are as high as 67% to 79% as reported by autopsy at home and abroad. Among them, 11% of patients with acute PE die within 1 hour after the onset of the disease. If the patients can be diagnosed and treated with thrombolytic therapy in time, the mortality rate can be lowered to 10% to 15%. There are a number of nonfatal PE and chronic pulmonary hypertension studies, but few studies of PE leading to cardiac arrest have been reported. Therefore, we explored this in this study.

At present, the formation and dissolution of thrombus mainly depend on the activity of the blood coagulation system and fibrinolysis system of the body. In the study of the coagulation system, tissue factor (TF) has been found to play a key role in the initiation of coagulation.\(^5\) TF is a low molecular weight transmembrane glycoprotein that binds to factor VIIa and initiates the exogenous coagulation system. Under normal circumstances, the endothelial cells in contact with circulating blood are not expressed by TF,\(^6\) but after injury of tissue vessels, TF is exposed to blood, and the exogenous coagulation pathway is initiated after rapid binding with FVIIa, and the formation of TF-FVIIa factor complex is also observed.\(^7\) This allows the intrinsic coagulation pathway and the extrinsic coagulation pathway to be related together to complete the coagulation process. However, another related factor, tissue factor pathway inhibitor (TFPI), can inhibit only one physiological substance of VIIa/TF activity relative to the TF initiating coagulation pathway.\(^8\) TFPI binds to FXa to generate TFPI-FXa complex,\(^9\) which directly inhibits the activity of FXa, thus inhibiting the coagulation activity of TF-FVII complex and the formation of thrombus. The balance regulation between TF and TFPI plays an important role in the coagulation and anticoagulation of the body.

The formation of thrombi depends on the coagulation system, whereas the activity of the fibrinolytic system determines the dissolution of thrombi. The fibrinolytic system of the body is mainly regulated by the balance between tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1).\(^10\) The balance of t-PA and PAI-1 establishes the balance between the formation and clearance of blood clots in the body.\(^11\) Under physiological conditions, the concentration of t-PA in the blood circulation is very low, while under the physiological or pathological changes (such as vascular injury or thrombosis), the t-PA synthesised and stored in the endothelial cells enters the blood circulation to activate and generate plasmin, so as to remove the blood clot, maintain vessel patency. Under physiological conditions, t-PA in endothelial cells provides anti-thrombotic properties to the vessel wall.\(^12\) PAI-1 is the other end of equilibrium, which is the inhibitor of t-PA. It inhibits the activity of t-PA by combining with t-PA to form t-PA/PAI-1 complex, and changes the fibrinolytic function balance. It is mainly found in the increase in plasma PAI-1 level, which is the main factor of arteriovenous thrombosis. Numerous studies have shown that the balance of t-PA and PAI-1
determines the fibrinolytic activity in the circulation, whereas impaired fibrinolytic system activity is one of the major contributors to deep vein thrombosis and PE.

In this study, the changes of TF and TFPI, t-PA and PAI-1 in cardiac arrest caused by PE and coagulation and fibrinolysis system after resuscitation were investigated. The aim is to present a theoretical basis for the resuscitation and treatment of patients with cardiac arrest caused by PE in clinical practice.

2 | MATERIALS AND METHODS

2.1 | Experimental animals

Twenty-one male Beijing Landrace pigs (10-12 weeks old, weighing 30 ± 2 kg, supplied by Beijing Green Source Weiye Farm) were fasted overnight before the experiment and allowed free access to water. The pig was given an intramuscular injection of midazolam 0.2 mg/kg and atropine 1 mg before surgery; the catheter was inserted via the marginal ear vein puncture. Anaesthesia was maintained by intravenous bolus injection of propofol 2 mg/kg and remifentanil 5 μg/kg with continuous intravenous infusion of pentobarbital 8 mg/kg/h and remifentanil 5 μg/kg/h. The end-tidal carbon dioxide partial pressure is monitored with an infrared carbon dioxide analyser, and the pressure is maintained at 30 to 40 mmHg by adjusting the ventilator parameters. Room temperature was maintained at 27°C. The corresponding vessel was separated through surgical anatomical operation for catheterization.

The study was reviewed by the Institutional Review Board of Capital Medical University, and all animals were treated in accordance with the Guide for the Care and Use of Laboratory Animals, Version 8, with steps taken to minimise suffering from experimental animals.

2.2 | Thrombus preparation

A 50 mL syringe is used to draw 50 mL porcine autologous venous blood, add 50 units of thrombin and place it at room temperature for half an hour. A steady state gel-like clot was cut into thrombus approximately 1.5 cm in diameter and rinsed three times with saline. A final volume of 10 to 15 mL of thrombus was obtained and suspended in saline from a 50 mL syringe.

2.3 | Experimental procedure

After completion of the surgical procedure, the animal was allowed to stabilise for 30 minutes and the underlying status data were recorded. The thrombus was then injected via a left external jugular vein catheter and injected within 1 minute until cardiac arrest, as indicated by a mean arterial pressure of <30 mmHg. After the thrombus was injected, the left external jugular catheter was removed and ventilator-assisted ventilation was discontinued. The various parameters required for cardiac arrest were recorded. CT pulmonary angiography was performed to assess PE. After completion of CT pulmonary angiography, a 50 mg dose of recombinant human tissue plasmin activator was injected into the pulmonary artery via a Swan-Ganz catheter. Cardiopulmonary resuscitation in accordance with the 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care was immediately initiated, epinephrine 0.02 mg/kg was administered as an intravenous bolus, with a ventilation pressure ratio of 30:2 and air-assisted ventilation with an artificial balloon. If ventricular fibrillation was indicated by ECG monitoring, an asynchronous 150 J defibrillation was performed with unsuccessful defibrillation, followed by 2 minutes of cardiopulmonary resuscitation and by another defibrillation within a 10-second interval. The quality of ECG and chest compression was monitored by a HeartSart MRx monitoring/defibrillator using Q-PCR technology. Restoration of spontaneous circulation is defined as the presence of an organised rhythm with a mean arterial pressure ≥60 mmHg for more than 10 minutes. Data were recorded immediately, 1, 2, 4 and 6 hours after recovery of spontaneous circulation.

Finally, the animal was euthanized by injection of an overdose of potassium chloride and propofol.

2.4 | Data recording and statistical analysis

Cardiac monitors monitor heart rate, blood pressure, central venous pressure and ECG. The changes of TF, TFPI, t-PA and PAI-1 in the blood were detected by ELISA method. The blood samples were collected immediately, 1, 2, 4 and 6 hours after the restoration of spontaneous circulation.

Quantitative data are presented as mean ± standard deviation for normal distribution and as median (25% percentile, 75% percentile) for non-normal distribution. Repeated measures analysis of variance was used for normally distributed data of surviving animals after successful resuscitation. A two-sided P-value <.05 was considered statistically significant. SPSS 21.0 statistical software was used for statistical analysis.
3 | RESULTS

3.1 | Outcome of study animals

Seventeen pigs had cardiac arrest after intravenous injection of 10 to 15 mL of thrombus, and the other four had cardiac arrest after additional 5 to 8 mL of thrombus. Necropsy of animals revealed pulmonary infarction and thrombus in the pulmonary arteries (Figure 1) and seven of these test animals developed ventricular fibrillation. Arterial blood was drawn during the 3-minute duration of the cardiac arrest and a CT pulmonary angiogram was performed for cardiopulmonary resuscitation. Eleven test animals returned to spontaneous circulation after cardiopulmonary resuscitation, of which two survived for 1 hour and nine survived for 6 hours (Figure 2).

3.2 | Analysis of TF, TFPI, t-PA and PAI-1 data

The results are presented in Table 1. After successful modelling of the resuscitation model for cardiac arrest, TF levels were decreased at each stage compared with basal status, but were not statistically different ($P > .05$). Compared with the basal state, the levels of TFPI were statistically significant ($P < .05$) at the immediate recovery of spontaneous circulation, 1, 2, 4 and 6 hours after the recovery of spontaneous circulation, and the levels of t-PA were statistically significant ($P < .05$) at the acute recovery of cardiac arrest and spontaneous circulation. There was a statistical difference in PAI-1 level at 1, 2, 4 and 6 hours after recovery of spontaneous circulation ($P < .05$), and no statistical difference in PAI-1 level at each stage compared with basal state ($P > .05$).

4 | DISCUSSION

In this experiment, there was no statistically significant difference in the final blood TF level compared with the basal state ($P > .05$). TF is the initiating factor of exogenous coagulation function. Under normal circumstances, vascular endothelial cells do not express TF, but under the pathological conditions such as vascular injury, TF is exposed to blood subcutaneously, TF is combined with

---

**FIGURE 1** Gross sample of pulmonary artery thromboembolism lung

**FIGURE 2** Trial process and animal outcome
FVII to form complex and FIX and FX are activated, so as to form FIXa and FXa. It eventually forms thrombin, resulting in fibrin deposition and platelet activation to form thrombus. Zhang et al.\textsuperscript{15} found that after 3 and 8 hours of embolization, TF expression of the pulmonary artery distal to embolization was significantly lower than that of the pulmonary artery and normal pulmonary artery. There was no significant difference in TF expression between the embolized pulmonary arteries and normal pulmonary arteries. Considering the possible explanation, early PE provokes the body’s self-protection mechanism to prevent thrombus extension to the distal and non-embolic sites.

TFPI is likewise secreted primarily by the vascular endothelium and specifically inhibits the TF-mediated coagulation pathway.\textsuperscript{16-18} TFPI inhibits TF/VIIa activity and plays an important role in the regulation of negative feedback on coagulation. In this experiment, the level of TFPI was markedly increased after resuscitation of cardiac arrest caused by PE ($P < .05$). This suggests that TFPI plays a regulatory role in coagulation activity and, consequently, in the development of thrombi, in modulating anticoagulation. Cisowska-Czajka et al.\textsuperscript{19} reported that the level of TFPI in the pulmonary artery at the embolization site was higher than that in the distal pulmonary artery at the embolization site in some time after acute PE. There are other reports of no association between PE and plasma TFPI levels.\textsuperscript{20,21} The reasons for inconsistent study results may be related to different study time points and study methods, and there may be other different influencing factors. Therefore, TFPI observation in the early stage of embolization may be helpful for the change of the disease condition and the prognosis of embolization.

TFPI is likewise secreted primarily by the vascular endothelium and specifically inhibits the TF-mediated coagulation pathway.\textsuperscript{16-18} TFPI inhibits TF/VIIa activity and plays an important role in the regulation of negative feedback on coagulation. In this experiment, the level of TFPI was markedly increased after resuscitation of cardiac arrest caused by PE ($P < .05$). This suggests that TFPI plays a regulatory role in coagulation activity and, consequently, in the development of thrombi, in modulating anticoagulation. Cisowska-Czajka et al.\textsuperscript{19} reported that the level of TFPI in the pulmonary artery at the embolization site was higher than that in the distal pulmonary artery at the embolization site in some time after acute PE. There are other reports of no association between PE and plasma TFPI levels.\textsuperscript{20,21} The reasons for inconsistent study results may be related to different study time points and study methods, and there may be other different influencing factors. Therefore, TFPI observation in the early stage of embolization may be helpful for the change of the disease condition and the prognosis of embolization.

TFPL is likewise secreted primarily by the vascular endothelium and specifically inhibits the TF-mediated coagulation pathway.\textsuperscript{16-18} TFPI inhibits TF/VIIa activity and plays an important role in the regulation of negative feedback on coagulation. In this experiment, the level of TFPI was markedly increased after resuscitation of cardiac arrest caused by PE ($P < .05$). This suggests that TFPI plays a regulatory role in coagulation activity and, consequently, in the development of thrombi, in modulating anticoagulation. Cisowska-Czajka et al.\textsuperscript{19} reported that the level of TFPI in the pulmonary artery at the embolization site was higher than that in the distal pulmonary artery at the embolization site in some time after acute PE. There are other reports of no association between PE and plasma TFPI levels.\textsuperscript{20,21} The reasons for inconsistent study results may be related to different study time points and study methods, and there may be other different influencing factors. Therefore, TFPI observation in the early stage of embolization may be helpful for the change of the disease condition and the prognosis of embolization.

The fibrinolytic system, like the coagulation system, is an important part of the body’s regulation of physiological balance. PA is the major component of the fibrinolytic system and includes t-PA and urokinase plasminogen activator (u-PA).\textsuperscript{22-24} t-PA is a key enzyme in blood vessels that is synthesised primarily in endothelial cells and stored, and used to treat thrombosis.\textsuperscript{25} Under the influence of certain factors (such as vascular injury or thrombosis, etc.), large amounts of endothelial cells can be released into blood. Fibrinolytic enzymes are produced and activated to remove blood clots from the blood vessels to maintain vessel patency. Under physiological conditions, t-PA in endothelial cells provides antithrombotic properties to the vessel wall. In this study, blood t-PA levels were significantly increased at 1, 2, 4 and 6 hours after recovery of spontaneous circulation compared with the basal state, which indicated that the body was injured and thrombosed under the stress of PE and cardiac arrest, and the body’s fibrinolytic system was activated by a large amount of t-PA release into the circulation. It is then used to dissolve the thrombus. A number of studies have found that elevated plasma t-PA antigen

### Table 1: Coagulation and fibrinolysis data analysis

|                  | Basal status | Heart arrest | ROSC 0 | ROSC 1 hour | ROSC 2 hours | ROSC 4 hours | ROSC 6 hours |
|------------------|--------------|--------------|--------|-------------|--------------|--------------|--------------|
| TF (ng/L)        | 288.99 ± 30.84 | 290.78 ± 32.86 | 290.84 ± 37.62 | 292.16 ± 40.11 | 292.03 ± 31.87 | 293.69 ± 30.17 | 293.18 ± 28.38 |
| TFPI (ng/L)      | 85.41 ± 6.09  | 86.40 ± 5.12  | 89.69 ± 6.35\textsuperscript{a} | 93.83 ± 7.19\textsuperscript{b} | 103.13 ± 8.24\textsuperscript{a} | 109.08 ± 9.82\textsuperscript{a} | 115.50 ± 8.67\textsuperscript{a} |
| t-PA (μg/L)      | 13.36 ± 1.69  | 13.67 ± 1.76  | 13.45 ± 1.87 | 14.57 ± 1.77\textsuperscript{b} | 15.39 ± 1.59\textsuperscript{a} | 15.33 ± 2.02\textsuperscript{a} | 15.08 ± 1.59\textsuperscript{b} |
| PAI-1 (μg/mL)    | 20.02 ± 0.70  | 20.02 ± 1.37  | 20.32 ± 1.56 | 20.66 ± 0.82 | 20.62 ± 0.54 | 20.75 ± 0.71 | 20.99 ± 0.90 |

Abbreviations: PAI-1, plasminogen activator inhibitor-1; TF, tissue factor; TFPI, tissue factor pathway inhibition; t-PA, tissue plasminogen activator.

\textsuperscript{a}0.1 < P < .05 vs basal status basal status.

\textsuperscript{b}P < .01 vs basal status.
levels and/or decreased activity are risk factors for cardiovascular and cerebrovascular disease with thrombosis.

PAI-1 is an inhibitor of t-PA, which inhibits the activity of t-PA by combining with t-PA to form t-PA/PAI-1 complex. The changes of fibrinolytic function balance are mainly found in the increase of plasma PAI-1 level, which is the main factor of arteriovenous thrombosis. Numerous studies have shown that the balance of t-PA and PAI-1 determines the fibrinolytic activity in the circulation, whereas impaired fibrinolytic system activity is a major contributor to deep vein thrombosis and PE. There was no significant difference in the levels of PAI-1 between different stages in this study. It is possible that PAI-1 did not change significantly in the resuscitation model of acute PE. Alternatively, a body with a short experimental time frame (up to 6 hours) did not produce significant changes under stress. Clinical studies have shown that PAI-1 mRNA expression in embolised pulmonary arteries and adjacent vascular endothelial cells in patients with chronic PE is significantly higher than PAI-1 mRNA in non-embolised pulmonary artery endothelial cells, suggesting that endothelial cells also play a role in preventing thrombus lysis.

5 CONCLUSION

TFPI has a certain influence on the coagulation and thrombosis regulation of the body, and the increase of fibrinolytic activity has a positive promoting effect on the thrombolysis. The proposed mechanism is shown in Figure 3. It provided the theoretical basis for clinical treatment of thrombotic diseases.

CONFLICT OF INTEREST
The authors declared no potential conflicts of interest.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE
The study was reviewed by the Institutional Review Board of Capital Medical University, and all animals were treated in accordance with the Guide for the Care and Use of Laboratory Animals, Version 8, with steps taken to minimise suffering from experimental animals.

DATA AVAILABILITY STATEMENT
The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

REFERENCES

1. Kürkciyan I, Meron G, Sterz F, et al. Pulmonary embolism as cause of cardiac arrest. Arch Intern Med. 2000;160(10):1529-1535.

2. Varol Y. The incidence of chronic thromboembolic pulmonary hypertension secondary to acute pulmonary thromboembolism. Tuberk Toraks. 2014;62(3):199-206.

3. Klokk FA, Huismen MV. Continued anticoagulation for unprovoked venous thromboembolism: guidance through the maze of recent studies. Ned Tijdschr Geneeskd. 2017;161:D1679.

4. Maestre PA, González GA, Monreal BM. Update on the risk stratification of acute symptomatic pulmonary embolism. Rev Clin Esp. 2017;217(6):342-350.

5. Rao LV, Rapaport SI. Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation. Proc Natl Acad Sci USA. 2014;85(18):6687-6691.

6. Drake TA. Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line. J Cell Biol. 2009;109(1):389-395.

7. Hjortoe GM, Petersen LC, Albrektssen T, et al. Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-23l cells is mediated by PAR-2 and results in increased cell migration. Blood. 2004;103(8):3029-3037.

8. Cui XY, Skretting G, Tinholt M, et al. A novel hypoxia response element regulates oxygen-related repression of tissue factor pathway inhibitor in the breast cancer cell line MCF-7. Thrombosis Research. 2017;157:111-116.

9. Wood JP, Petersen HH, Yu B, et al. TFPIα interacts with FVα and FXα to inhibit prothrombinase during the initiation of coagulation. Blood Adv. 2017;109(1):27-2017.

10. Gouda MM, Bhandary YP. Curcumin down-regulates IL-17A mediated p55-fibrinolytic system in bleomycin induced acute lung injury in vivo. J Cell Biochem. 2018;119(9):7285-7299.

11. Bi J, Zhang S, Du Z, et al. Peripheral serotonin regulates post-operative intra-abdominal adhesion formation in mice. Sci Rep. 2017;7(1):10001.

12. Bystricky B, Jurisova S, Karaba M, et al. Relationship between circulating tumor cells and tissue plasminogen activator in patients with early breast cancer. Anticancer Res. 2017;37(4):1787-1791.

13. Vuckovic BA, Djeric MJ, Tomic BV, et al. Influence of decreased fibrinolytic activity and plasminogen activator inhibitor-1 4G/5G polymorphism on the risk of venous thrombosis. Blood Coagul Fibrinolysis. 2018;29(1):19.

14. Hegemann G, Schmitz W. The suprainguinal vessel resection in arteriovenous thrombosis. J Urol Nephrol. 1998;61(1):3-9.

15. Zhang J-X, Chen Y-L, Zhou Y-L, et al. Expression of tissue factor in rabbit pulmonary artery in an acute pulmonary embolism model. World J Emerg Med. 2014;5(2):144-147.

16. Kostovski E, Dahm AEA, Iversen N, et al. Melatonin stimulates factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-23l cells is mediated by PAR-2 and results in increased cell migration. Blood. 2004;103(8):3029-3037.

17. Klok FA, Huisman MV. Continued anticoagulation for unprovoked venous thromboembolism: guidance through the maze of recent studies. Ned Tijdschr Geneeskd. 2017;161:D1679.

18. Maestre PA, González GA, Monreal BM. Update on the risk stratification of acute symptomatic pulmonary embolism. Rev Clin Esp. 2017;217(6):342-350.

19. Tao LV, Rapaport SI. Activation of factor VII bound to tissue factor: a key early step in the tissue factor pathway of blood coagulation. Proc Natl Acad Sci USA. 2014;85(18):6687-6691.

20. Drake TA. Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line. J Cell Biol. 2009;109(1):389-395.

21. Hjortoe GM, Petersen LC, Albrektssen T, et al. Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-23l cells is mediated by PAR-2 and results in increased cell migration. Blood. 2004;103(8):3029-3037.

22. Cui XY, Skretting G, Tinholt M, et al. A novel hypoxia response element regulates oxygen-related repression of tissue factor pathway inhibitor in the breast cancer cell line MCF-7. Thrombosis Research. 2017;157:111-116.

23. Wood JP, Petersen HH, Yu B, et al. TFPIα interacts with FVα and FXα to inhibit prothrombinase during the initiation of coagulation. Blood Adv. 2017;109(1):27-2017.

24. Gouda MM, Bhandary YP. Curcumin down-regulates IL-17A mediated p55-fibrinolytic system in bleomycin induced acute lung injury in vivo. J Cell Biochem. 2018;119(9):7285-7299.

25. Bi J, Zhang S, Du Z, et al. Peripheral serotonin regulates post-operative intra-abdominal adhesion formation in mice. Sci Rep. 2017;7(1):10001.

26. Bystricky B, Jurisova S, Karaba M, et al. Relationship between circulating tumor cells and tissue plasminogen activator in patients with early breast cancer. Anticancer Res. 2017;37(4):1787-1791.

27. Vuckovic BA, Djeric MJ, Tomic BV, et al. Influence of decreased fibrinolytic activity and plasminogen activator inhibitor-1 4G/5G polymorphism on the risk of venous thrombosis. Blood Coagul Fibrinolysis. 2018;29(1):19.

28. Hegemann G, Schmitz W. The suprainguinal vessel resection in arteriovenous thrombosis. J Urol Nephrol. 1998;61(1):3-9.

29. Zhang J-X, Chen Y-L, Zhou Y-L, et al. Expression of tissue factor in rabbit pulmonary artery in an acute pulmonary embolism model. World J Emerg Med. 2014;5(2):144-147.

30. Kostovski E, Dahm AEA, Iversen N, et al. Melatonin stimulates release of tissue factor pathway inhibitor from the vascular endothelium. Blood Coagul Fibrinolysis. 2013;22(4):254-259.

31. Ersayin A, Thomas A, Seyev L, et al. Catalytically inactive Glu-domainless factor Xa binds to TFPI and restores ex vivo coagulation in hemophilia plasma. Haematologica. 2017;102(12):haematol.2017.174037.

32. Dahlbäck B. Novel insights into the regulation of coagulation by factor V isoforms, tissue factor pathway inhibitor α, and protein S. J Thromb Haemost. 2017;15(7):1241-1250.

33. Cisowska-Czajka ME, Mazij MP, Kotschy MH, et al. Plasma concentrations of tissue factor and its inhibitor in chronic thromboembolic pulmonary hypertension: a step to learn more about etiology of the disease. Kardiol Pol. 2016;74(11):1332.
20. Kamikura Y, Wada H, Yamada A, et al. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction. *Am J Hematol*. 2010;55(4):183-187.
21. Sun Y, Wu RH, Liu WH, et al. Analysis of the dynamic change of TF, TFPI and IL-1beta in plasma of patients with acute leukemia. *Zhongguo Shi Yan Xue Ye Xue Za Zhi*. 2008;16(3):493.
22. Nicole O, Docagne F, Ali C, et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. *Nat Med*. 2001;7(1):59-64.
23. Dennler S. Direct binding of Smad3 and Smad4 to critical TGFbeta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. *EMBO J*. 2012;17(11):3091-3100.
24. Topol EJ, Califf RM, George BS, et al. Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction. *Circulation*. 2005;77(5):1100-1107.
25. Raffa GM, D’Ancona G, Sciaccia S, et al. Systemic or endoventricular thrombolysis to treat HeartWare left ventricle assist device thrombosis: a clinical dilemma. *Artif Organs*. 2015;6(39):526-529.
26. Booyse FM, Aikens ML, Grenett HE. Endothelial cell fibrinolysis: transcriptional regulation of Fibrinolytic protein gene expression (t-PA, u-PA, and PAI-1) by low alcohol. *Alcohol Clin Exp Res*. 2006;23(6):1119-1124.
27. Chandler WL, Mornin D, Whitten RO, et al. Insulin, cortisol and catecholamines do not regulate circadian variations in fibrinolytic activity. *Thromb Res.* 2009;58(1):1-12.

How to cite this article: Tong N, Li C. Changes of fibrinolytic system in thrombolytic resuscitation of pulmonary thromboembolism-induced cardiac arrest model. *Int Wound J*. 2021;1–7. [https://doi.org/10.1111/iwj.13589]